Medline, Inc. Class A (MDLN)
NASDAQ:MDLN
Want to see MDLN full AI Analyst Report?
Top Page
Medline
(NASDAQ:MDLN)
Select Model
Select Model
Rating:61Neutral
Price Target:
$39.00
▼(-18.14% Downside)
Action:Reiterated
Date:06/13/26
The score is primarily supported by strong revenue momentum, improving gross margins, and steady-to-improving free cash flow. It is held back by elevated leverage and less consistent earnings-to-cash conversion, with technicals still weak (negative MACD and trading below key longer-term averages) and valuation appearing demanding at a ~31 P/E.
Positive Factors
Revenue scaling and margin expansion
Sustained top-line growth alongside a multi-percentage-point gross margin rise signals durable improvements in pricing, mix, and cost control. Over 2–6 months this supports higher incremental profitability, more operating leverage as volumes scale, and greater capacity to reinvest in distribution and product offerings.
Negative Factors
Elevated leverage and rising debt-to-equity
A materially higher leverage profile reduces financial flexibility and increases susceptibility to cash-flow shocks. With debt roughly matching or exceeding equity and leverage rising in 2025, the company faces greater covenant and refinancing risk, limiting ability to fund growth or absorb demand disruptions.
Read all positive and negative factors
Positive Factors
Negative Factors
Revenue scaling and margin expansion
Sustained top-line growth alongside a multi-percentage-point gross margin rise signals durable improvements in pricing, mix, and cost control. Over 2–6 months this supports higher incremental profitability, more operating leverage as volumes scale, and greater capacity to reinvest in distribution and product offerings.
Read all positive factors
Medline (MDLN) vs. SPDR S&P 500 ETF (SPY)
Market Cap
$49.04B
Dividend YieldN/A
Average Volume (3M)12.49M
Price to Earnings (P/E)31.5
Beta (1Y)1.34
Revenue Growth12.07%
EPS Growth-22.07%
CountryUS
Employees43,000
SectorHealthcare
Sector Strength45
IndustryMedical - Instruments & Supplies
Share Statistics
EPS (TTM)1.21
Shares Outstanding845,606,200
10 Day Avg. Volume11,964,805
30 Day Avg. Volume12,487,356
Financial Highlights & Ratios
PEG Ratio-4.97
Price to Book (P/B)3.18
Price to Sales (P/S)1.20
P/FCF Ratio26.29
Enterprise Value/Market Cap0.85
Enterprise Value/Revenue1.43
Enterprise Value/Gross Profit5.96
Enterprise Value/Ebitda15.29
Forecast
1Y Price Target
$51.95Price Target Upside9.04% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering20
EPS Forecast (FY)1.51
Revenue Forecast (FY)$31.08B
Medline Business Overview & Revenue Model
Company Description
Medline Inc. is a global manufacturer of medical and surgical products, catering to a broad spectrum of healthcare providers. Their clientele includes hospitals, surgical centers, physician practices, post-acute care facilities, and nursing homes,...
How the Company Makes Money
null...
Medline Financial Statement Overview
Summary
Income Statement
74
Positive
Balance Sheet
58
Neutral
Cash Flow
63
Positive
| Breakdown | TTM | Dec 2025 | Dec 2024 | Dec 2023 |
|---|---|---|---|---|
Income Statement | ||||
| Total Revenue | 29.14B | 28.43B | 25.51B | 23.23B |
| Gross Profit | 7.01B | 7.52B | 6.29B | 5.22B |
| EBITDA | 2.73B | 1.95B | 3.53B | 2.59B |
| Net Income | 964.00M | 1.16B | 1.20B | 234.00M |
Balance Sheet | ||||
| Total Assets | 39.01B | 38.48B | 35.98B | 36.12B |
| Cash, Cash Equivalents and Short-Term Investments | 2.24B | 1.94B | 250.00M | 1.58B |
| Total Debt | 12.64B | 12.56B | 16.90B | 16.83B |
| Total Liabilities | 19.66B | 19.20B | 19.45B | 19.14B |
| Stockholders Equity | 11.27B | 10.74B | 16.52B | 16.98B |
Cash Flow | ||||
| Free Cash Flow | 1.52B | 1.30B | 1.41B | 1.40B |
| Operating Cash Flow | 1.52B | 1.74B | 1.77B | 1.69B |
| Investing Cash Flow | -469.00M | -474.00M | -1.49B | -312.00M |
| Financing Cash Flow | 547.00M | 399.00M | -1.61B | -191.00M |
Medline Peers Comparison
UnderperformOutperform
Sector (51)
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
68 Neutral | $3.99B | 28.91 | 8.95% | ― | 11.34% | 12.26% | |
64 Neutral | $40.10B | 35.80 | 4.54% | 2.13% | 2.39% | -24.85% | |
61 Neutral | $49.04B | 31.51 | 6.87% | ― | 12.07% | -22.07% | |
57 Neutral | $3.59B | 76.10 | 2.19% | ― | -10.76% | ― | |
57 Neutral | $5.76B | -5.61 | -28.27% | 1.11% | -6.61% | -812.37% | |
51 Neutral | $7.86B | -0.30 | -43.30% | 2.27% | 22.53% | -2.21% | |
49 Neutral | $10.75B | -9.60 | -16.43% | 2.75% | -4.79% | -78.01% |
* Healthcare Sector Average
MDLN
Medline
37.09
-3.91
-9.54%
BAX
Baxter International
20.46
-9.20
-31.03%
BDX
Becton Dickinson
145.16
14.81
11.36%
ICUI
ICU Medical
142.41
12.44
9.57%
MMSI
Merit Medical Systems
67.68
-25.22
-27.15%
TFX
Teleflex
127.87
11.67
10.04%
Medline Corporate Events
Executive/Board ChangesShareholder Meetings
Medline Shareholders Back Board, Auditor and Pay Practices
Positive
Jun 12, 2026
On June 11, 2026, Medline Inc. held its 2026 Annual Meeting of Stockholders, at which investors elected all 12 board nominees to one-year terms expiring at the 2027 annual meeting and ratified Ernst Young LLP as independent auditor for the fiscal...
Business Operations and StrategyPrivate Placements and FinancingRegulatory Filings and Compliance
Medline Completes Major Refinancing and Secondary Share Offering
Positive
Jun 2, 2026
On May 28, 2026, Medline completed a major refinancing by issuing $1.25 billion of 5.000% senior secured notes due 2031 and $750 million of 5.250% senior secured notes due 2033, while simultaneously establishing a new $2.75 billion senior secured ...
Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.